“Our study illustrates one of the most important achievements in IVF treatment,” said Dr. Rifaat Salem, Medical Director and PRC founder. “With our in-house aCGH screening, we can significantly increase pregnancy rates and reduce multi-fetal pregnancies."
Torrance, CA (PRWEB) May 15, 2012
Pacific Reproductive Center (PRC), a global leader in in vitro fertilization (IVF) technology and treatment, recently pioneered the world’s first randomized study utilizing Array Comparative Genomic Hybridization (aCGH) to improve pregnancy rates and reduce multiple pregnancies in infertile patients. aCGH is a new genetic testing technology that enables the screening of all 24 chromosomes before embryo transfer.
Published in the current issue of the Journal of Molecular Cytogenetics, the research applied the 24sure technology developed in collaboration with UK-based BlueGenome, Ltd. PRC is the first IVF center in the world to fully integrate aCGH technology to select single blastocysts for transfer to ensure a healthy pregnancy.
The study aimed to reduce multiple gestation risk and increase pregnancy outcomes by placing only one chromosomally normal embryo inside the womb after using the aCGH technology. The study randomized 103 IVF cycles using two groups, the treatment (aCGH) group and the control (morphology assessment only) group. Conventional embryo selection based on morphological evaluation resulted in a 41.7 percent ongoing pregnancy rate in the control group, while a 69.1 percent pregnancy rate was achieved in the aCGH testing group.
Historically, single embryo transfer has been underutilized because of its lower pregnancy chances. However, the PRC data shows that multiple embryo transfers may no longer be required to achieve successful pregnancies. Instead, aCGH technology can allow one chromosomally normal embryo to be successfully transferred, thus increasing pregnancy rates and reducing the risk of multiple pregnancies.
“Our study illustrates one of the most important achievements in IVF treatment,” said Dr. Rifaat Salem, Medical Director and PRC founder. “With our in-house aCGH screening, we can significantly increase pregnancy rates and reduce multi-fetal pregnancies with a single embryo transfer.”
“24sure comprehensive chromosomal screening has been clinically proven to be the most effective means to select chromosomally normal embryo(s) for transfer to ensure a healthy pregnancy for infertile patient s,” said Dr. Zhihong Yang, Executive Director for ART and PRG Laboratories at PRC. “As a clinical scientist, I am happy to be a part of the new technology.”
Dr. Salem and his highly trained and compassionate staff have helped literally thousands of patients become parents, usually after they had undergone multiple unsuccessful procedures elsewhere. PRC’s motto of "Helping Create Families Everyday" has indeed been put into practice; the center has been helping couples achieve their dream of having a family since 1990. Pacific Reproductive Center has been featured by the media on both local and national levels because of its incredible success rate in treating infertility.
With its unique advantage of in-house laboratory services, PRC Fertility has the ability to produce highly accurate and credible results in less than 12 hours.
To download a copy of the PRC Fertility’s pioneer study, please visit:
If you would like information about this topic or to schedule an interview with Dr. Salem and Dr. Yang, please call Julie Miller at 951-316-6909 or email her at email@example.com.